CAR T-cell therapy generates lasting remissions in patients with multiple myeloma

(Dana-Farber Cancer Institute) In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found.